Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

PanTher Therapeutics today announced that the first patient has been treated with PTM-101 in a Phase 1b trial in pancreatic ductal adenocarcinoma.

Purpose Intraperitoneal (IP) cisplatin and intravenous (IV) or IP paclitaxel constitute a standard therapy for optimally debulked ovarian cancer. Bevacizumab prolongs progression-free survival (PFS) ...

Baccatin III is a key precursor for the chemotherapy drug Taxol, and scientists have now figured out how it’s made in yew trees.

Original Medicare covers medically necessary IV infusion therapy in clinics and at home. Medicare Advantage (Part C) also covers these services, but out-of-pocket costs vary by plan.

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral disease.

Topline data were announced from a phase 2/3 trial evaluating tovecimig plus paclitaxel in patients with advanced biliary tract cancer.

Liporaxel demonstrated non-inferiority in progression-free survival and superiority in overall survival compared to intravenous paclitaxel as a second-line therapy for patients with advanced gastric ...

The single-dose 100 mg vial for intravenous use is approved for metastatic breast cancer.

WASHINGTON, DC—A sirolimus drug-coated balloon (DCB) is noninferior to paclitaxel-coated DCBs for the treatment of femoropopliteal artery disease, according to data from the SIRONA trial, the first ...

The launch of the lyophilized powder for injection containing 100 mg of paclitaxel in a single-dose vial for intravenous use follows approval by the FDA on Oct. 8.